Related Experiment Video

Updated: May 28, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors

Thu N T Nguyen1, Rahman S Z Saleem, Micah J Luderer

  • 1Department of Chemistry, Michigan State University, East Lansing, 48824, United States.

ACS Chemical Biology
|October 19, 2011
PubMed

Insights

Natural product-derived Chk2 inhibitors protect normal cells from radiation damage by activating the ATM-dependent DNA repair pathway. This offers a potential radioprotective strategy for cancer therapy, particularly in p53 wild-type tumors.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Radioprotection

Background:

  • Ionizing radiation (IR) triggers the ataxia telangiectasia mutated (ATM) pathway, influencing cell fate through apoptosis or DNA repair.
  • The checkpoint kinase 2 (Chk2) is a key mediator in the DNA damage response pathway.
  • Targeting Chk2 offers potential for adjuvant cancer therapy, as Chk2 inhibition can promote normal cell cycle arrest and DNA repair, while many tumors evade these checkpoints.

Purpose of the Study:

  • To identify and characterize natural product-derived Chk2 inhibitors with radioprotective potential.
  • To investigate the ATM-dependent Chk2-mediated mechanism of radioprotection in normal and cancer cells.
  • To evaluate the efficacy of these inhibitors in normal human cells beyond T-cells.

Main Methods:

  • Screening of natural product-derived compounds for Chk2 inhibitory activity.
  • Assessment of ATM-dependent Chk2-mediated radioprotection in various human cell types.
  • Analysis of Chk2 autophosphorylation at Ser516 in response to treatment.
  • Evaluation of cell survival following ionizing radiation exposure.

Main Results:

  • A class of natural product-derived Chk2 inhibitors, including indoloazepine 1, demonstrated significant ATM-dependent Chk2-mediated radioprotection in normal and p53 wild-type cells.
  • The radioprotective effect was not observed in p53 mutant cells, which constitute a significant portion of human cancers.
  • Several hymenialdisine analogues effectively inhibited Chk2 at nanomolar concentrations and enhanced normal cell survival post-ionizing radiation.
  • This study is the first to report radioprotection in human cells other than T-cells, highlighting the necessity of a functional ATM pathway.

Conclusions:

  • Natural product-derived Chk2 inhibitors can confer radioprotection to normal cells via an ATM-dependent pathway.
  • These compounds represent a promising strategy for developing radioprotective agents in cancer therapy, especially for patients with p53 wild-type tumors.
  • The findings underscore the importance of the ATM pathway in mediating the radioprotective effects of Chk2 inhibitors.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...